Special advertising section.
SPECIAL ADVERTISING SECTION
Asthma treatment can be significantly reduced through appropriate educational interventions according to a study recently published in Disease Management and Health Outcomes. The population-based study, titled "Economic Impact of an Asthma Education Program on Medical Care Utilization," was conducted by Rutgers University College of Pharmacy in conjunction with National Prescription Administrators (NPA), a New Jersey-based prescription benefit management (PBM) company. The goal of the study was to determine the economic impact of an asthma education program from the perspective of a third-party payer.
Asthma is a common chronic respiratory disorder affecting 14 to 15 million Americans.
All of the 5,527 patients involved in the study were members of a union health and welfare fund located in the northeastern part of the United States. NPA, the nation's largest truly independent prescription benefit manager, provides Rx benefit services to more than 7.5 million plan members and their families through over 1,000 major corporations, union groups, insurance companies, government organizations and managed care organizations.
The asthma education program encompassed: 1) therapy management interventions with physicians to ensure that patients were using the most appropriate asthma medications; 2) communication with physicians to improve medication compliance according to the guidelines established by the National Heart, Lung, and Blood Institute (NHLBI); 3) distribution of asthma educational materials to patients; and 4) compliance intervention through direct communication with physicians and, if necessary, patients.
The results of the Rutgers/NPA study showed that total asthma treatment costs decreased from $499.00 per patient to $415.00, a reduction of 17 percent in direct costs of therapy. Depending on the size of a sponsoring organization's card member population, this cost reduction can mean significant savings to a benefit plan. The individual components of the cost savings, expressed as average costs per patient in the intervention group, were as follows:
NPA Senior VP Robert M. Voytovich, PharmD, says that increased patient and physician awareness helps patients manage their asthma and improves patient outcomes. "This is particularly good news from the perspective of the patient as well as the employer in terms of reduced absenteeism, improved quality of life, and reduced medical and pharmacy costs. We are gratified with the positive outcomes demonstrated by this study, and the established role NPA can fulfill in managing overall costs for our clients." Voytovich further emphasizes the importance in collaborating with a prestigious academic institution like Rutgers to conduct the study.
A follow-up study will be released in mid2001 using the same data, but with a focus on the asthma prescription therapies that were employed. The initial study has already enabled NPA's clients to clear the air in managing the significant overall costs of asthma. Asthma affects the lives of 15 million Americans and their families. Hopefully, the results will help us all breathe more easily.
Call NPA at 800-526-7813 or visit us at www.npanet.com.
NPA and Rutgers University Collaborate to Reduce Asthma Costs. Business and Health 2001;6.
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with CeCi Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and CeCi Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 26th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More